Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotyp...
Saved in:
Main Authors: | Susanna Esposito, Nicola Principi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2015/591580 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)
by: Tao Chen, et al.
Published: (2022-07-01) -
A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
by: Ting-An Yen, et al.
Published: (2025-02-01) -
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
by: Alane Izu, et al.
Published: (2025-12-01) -
Estimation of invasive pneumococcal disease dynamics parameters and the impact of conjugate vaccination in Australia
by: Karyn L. Sutton, et al.
Published: (2007-12-01) -
Respiratory Infection and Otitis Media Visits in Relation to Pneumococcal Conjugate Vaccine Use in Saskatchewan
by: Ngoc-Hang Khuc, et al.
Published: (2013-01-01)